What is Elpiscience Biopharma?
Headquartered in Shanghai, Elpiscience Biopharma operates as a specialized clinical-stage biopharmaceutical entity dedicated to the discovery and development of next-generation cancer immunotherapies. The company leverages a robust research framework to address unmet medical needs in oncology, focusing on innovative therapeutic modalities that modulate the immune system to combat malignant tumors. By integrating deep scientific expertise with a strategic approach to drug development, Elpiscience has established itself as a key player in the global biotech ecosystem, bridging the gap between laboratory discovery and clinical application.
How much funding has Elpiscience Biopharma raised?
Elpiscience Biopharma has raised a total of $225M across 3 funding rounds:
Series A
$20M
Series B
$100M
Series C
$105M
Series A (2017): $20M with participation from Lilly Asia Ventures
Series B (2019): $100M led by Hyfinity Investments
Series C (2021): $105M supported by Pluto Connection Limited, Cormorant Asset Management, Maison Capital, Greater Bay Area Homeland Development Fund, and Superstring Capital
Key Investors in Elpiscience Biopharma
Cormorant Asset Management
A prominent life sciences investment firm with over $3B of assets under management, focusing on fundamental scientific principles to support innovative biotech companies.
Maison Capital
An investment firm emphasizing long-term perspectives and in-depth research, dedicated to fostering partnerships and improving quality of life through strategic capital allocation.
Lilly Asia Ventures
A leading biomedical venture capital firm that acts as a trusted partner for entrepreneurs developing breakthrough products to treat diseases and improve human health.
What's next for Elpiscience Biopharma?
With the recent influx of capital, Elpiscience Biopharma is well-positioned to accelerate its clinical trial programs and expand its therapeutic portfolio. The strategic focus will likely shift toward scaling manufacturing capabilities and advancing lead candidates through late-stage clinical validation. As the company matures, the emphasis on long-term value creation and the pursuit of regulatory milestones will be paramount. Investors and industry observers will be monitoring the firm's progress in navigating the complex regulatory landscape and its ability to translate preclinical success into tangible patient outcomes, further cementing its role as a leader in the immunotherapy space.
See full Elpiscience Biopharma company page
